Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.

Vaccine strategies for glioblastoma: progress and future directions IMMUNOTHERAPY Jackson, C., Ruzevick, J., Brem, H., Lim, M. 2013; 5 (2): 155–67

Abstract

Recent advances in glioblastoma therapy have led to optimism that more effective therapies will improve outcomes. Immunotherapy is a promising approach that has demonstrated the potential to eradicate cancer cells with cellular-level accuracy while minimizing damage to surrounding healthy tissue. Several vaccination strategies have been evaluated for activity against glioblastoma in clinical trials. These include peptide vaccines, polyvalent dendritic cell vaccines, heat shock protein vaccines and adoptive immunotherapy. In this review, we highlight clinical trials representative of each of these approaches and discuss strategies for integrating these therapies into routine patient care.

View details for DOI 10.2217/IMT.12.155

View details for Web of Science ID 000314674800013

View details for PubMedID 23413907

View details for PubMedCentralID PMC4086484